{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-23-000038","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.188031+00:00","generated_at":"2026-06-08T16:26:24.655831+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Amneal Q3 net revenue $620M (+14% YoY); adjusted EBITDA $154M (+22%); guidance raised","bullets":["Net revenue $620M (+14% YoY); GAAP net income $10M ($0.06 EPS) vs loss $0.02 in Q3 2022.","Adjusted net income $60M; adjusted EBITDA $154M (+22%); adjusted EPS $0.19 vs $0.14.","Generics revenue +12%, AvKARE +25%, Specialty +9%; all segments contributed to growth.","FY2023 guidance affirmed after previously being raised; on track to launch 40+ generics; IPX203 on track for 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-23-000038","json":"https://secwatch.observer/filing/0001723128-23-000038.json","markdown":"https://secwatch.observer/filing/0001723128-23-000038.md","text":"https://secwatch.observer/filing/0001723128-23-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000038/0001723128-23-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000038/amrx-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:26:24.655831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2120233dfe7dc46de5cab71da618358542024c8b","claim":"Amneal Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: revenue $620 million, net income $10 million, EPS $0.06.","evidence_excerpt":"the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS ‒ Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 ‒ ‒ Q3 2023 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.19 ‒","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000038/0001723128-23-000038-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$620 million"},{"label":"Net income","value":"$10 million"},{"label":"EPS","value":"$0.06"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}